1 week Ago By Defense World Staff
The Goldman Sachs Group upgraded shares of Johnson & Johnson (NYSE:JNJ – Free Report) from a neutral rating to a buy rating in a research report released on Wednesday morning, Marketbeat reports. The Goldman Sachs Group currently has $172.00 target price on the stock, up from their previous target price of $157.
00.Several other analysts have also weighed in on the company. Bank of America lifted their target price on Johnson & Johnson from $159.
00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Barclays increased their target price on Johnson & Johnson from $159.
00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Citigroup reduced their price target on Johnson & Johnson from $185.
00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus dropped their price objective on shares of Johnson & Johnson from $170.
00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $170.
00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock.
Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $171.67.
View Our Latest Stock Analysis on Johnson & JohnsonJohnson & Johnson Stock PerformanceJNJ opened at $151.62 on Wednesday. The company has a debt-to-equity ratio of 0.
43, a quick ratio of 0.86 and a current ratio of 1.11.
Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.
The firm has a market cap of $365.39 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 2.
56 and a beta of 0.49. The business’s fifty day moving average is $159.
40 and its 200-day moving average is $155.21. Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Wednesday, January 22nd.
The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.
05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.
24%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.
44 billion. During the same period last year, the firm earned $2.29 EPS.
The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 10.
58 EPS for the current fiscal year. Insider Buying and Selling at Johnson & JohnsonIn other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th.
The stock was sold at an average price of $165.88, for a total value of $1,160,994.12.
Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.
00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th.
The shares were sold at an average price of $156.15, for a total value of $62,928.45.
Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.
60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.
16% of the company’s stock. Institutional Trading of Johnson & JohnsonHedge funds have recently bought and sold shares of the business. IFS Advisors LLC increased its position in shares of Johnson & Johnson by 138.
9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000.
Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000.
Finally, Conquis Financial LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
About Johnson & Johnson (Get Free Report)Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further ReadingFive stocks we like better than Johnson & JohnsonInsider Buying Explained: What Investors Need to KnowJPMorgan is a Buy, if You Can Handle The Volatility How to Know Which Cryptocurrency to Buy: A Guide for InvestorsUnited States Steel’s Crash: An Unmissable Buying OpportunityThe Significance of Brokerage Rankings in Stock SelectionRocket Lab Stock: Weathering the Storm, Time for a Comeback?.
